Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Liuying Township, Taiwan Clinical Trials

A listing of Liuying Township, Taiwan clinical trials actively recruiting patients volunteers.

RESULTS

Found (5706) clinical trials

This is a single-arm, multi-cohort, multi-center, Phase 2 study to determine the efficacy and safety of JCAR017 in adult subjects with aggressive B-cell NHL. The study will enroll subjects in Europe and Japan with DLBCL NOS (de novo or tFL), high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements …

Phase

All potential subjects must have documentation of an 8p11 translocation known to activate FGFR1 through the site's own cytogenetics laboratory.  Once documentation has been provided, the subject will then undergo screening to meet the rest of the inclusion/exclusion criteria.  Once a subject has completed screening and has enrolled into the …

Phase

The purpose of this study is to evaluate the efficacy and safety of pemigatinib in participants with previously treated locally advanced/metastatic or surgically unresectable solid tumor malignancies harboring activating FGFR mutations or translocations.  

Phase

The purpose of this study is to evaluate the safety and efficacy of pemigatinib plus pembrolizumab or pemigatinib alone versus the standard of care for participants with metastatic or unresectable urothelial carcinoma who are not eligible to receive cisplatin, are harboring FGFR3 mutation or rearrangement, and who have not received …

Phase

The purpose of this study is to assess the safety and efficacy of oral administration of itacitinib once daily for the prevention of cytokine release syndrome (CRS) in male or female participants aged 12 years or older and who are planning to receive tisagenlecleucel or axicabtagene ciloleucel immune effector cell …

Phase

Eligible participants will be determined based upon results from lab tests, pain questionnaires, and diagnostic procedures. Two out every three of the participants will receive the study medication and one out of every three will be receive a placebo. The medication is given by an intravenous (IV) infusion every 2 weeks …

Phase

Eligible participants will be determined based upon results from lab tests, pain questionnaires, and diagnostic procedures. Two out every three of the participants will receive the study medication and one out of every three will be receive a placebo. The medication is given by an intravenous (IV) infusion every 2 …

Phase

All trial-related visits, tests, and medications will be provided to participants at no cost. In addition, compensation for time and/or travel may be provided.  

Phase

All trial-related visits, tests, and medications will be provided to participants at no cost. In addition, compensation for time and/or travel may be provided.

Phase

People with recurrent or progressive brain metastases may be eligible for this trial.  All tumors will be submitted to the Alliance biorepository for tracking and processing.  Samples will undergo central biomarker testing.  Patient's tumor samples will be tested for the presence of mutations predicting sensitivity to each inhibitor.  Patients harboring …

Phase